Glycopyrroniumbromid Accord (Glycopyrronium Bromide)

Glycopyrroniumbromid Accord is indicated for specific clinical situations where reduction of secretions is desired.

• Preoperative reduction of salivary secretions to facilitate endotracheal intubation.
• Decrease of respiratory tract secretions during anesthesia to lower aspiration risk.
• Adjunctive use in surgical procedures requiring a dry field, such as oral or ENT surgery.
• Management of excessive secretions in patients with certain neurologic conditions when a short‑acting anticholinergic is needed.
• Facilitation of bronchoscopy by reducing airway mucus production.
• Preparation for diagnostic procedures such as endoscopy where secretions may obscure visualization.

The safety profile of Glycopyrroniumbromid Accord reflects the pharmacology of glycopyrronium bromide, an anticholinergic agent.

Common

• Dry mouth (xerostomia), a frequent anticholinergic effect.
• Transient facial flushing, usually mild and short‑lasting.
• Mild tachycardia, reflecting reduced vagal tone.
• Reduced sweating (anhidrosis), leading to less perspiration.

Serious

• Severe tachyarrhythmia, which may require cardiac monitoring.
• Acute urinary retention, particularly in patients with prostate enlargement.
• Hyperthermia due to impaired sweating, potentially dangerous in hot environments.
• Allergic reactions such as rash, angioedema, or anaphylaxis, requiring immediate medical attention.

When prescribing Glycopyrroniumbromid Accord, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status, as anticholinergic effects can increase heart rate and provoke arrhythmias.
• Evaluate renal and hepatic function; impaired clearance may prolong drug action.
• Use caution in patients with glaucoma, especially narrow‑angle type, due to potential intra‑ocular pressure rise.
• Avoid in individuals with known hypersensitivity to glycopyrronium bromide or other anticholinergics.
• Monitor for signs of urinary retention in males with prostatic hypertrophy.
• Consider temperature regulation in patients at risk of hyperthermia, as sweating may be reduced.
• Review concomitant medications that also possess anticholinergic properties to prevent additive effects.

Glycopyrroniumbromid Accord may interact with other agents that influence cholinergic pathways or cardiovascular function.

Avoid

• Other anticholinergic drugs (e.g., atropine, scopolamine) that could amplify anticholinergic side effects.
• Monoamine oxidase inhibitors (MAOIs) when combined with certain anesthetic agents, increasing risk of cardiovascular instability.

Use with caution

• Beta‑adrenergic agonists (e.g., albuterol) as combined tachycardia may occur.
• Drugs that affect renal excretion such as diuretics, potentially altering glycopyrronium clearance.
• Anesthetic agents that depress the respiratory system, requiring careful monitoring of secretions.
• Medications that prolong the QT interval, as additive cardiac effects are possible.